Sara L. T.
- Country
- Spain
- Department
- Oncology
Research Overview
- Evaluation of Safety and Efficacy of Elacestrant in Combination Therapies for Patients with Metastatic Breast Cancer: A Phase 1b/2 Open-Label Umbrella Study
- Evaluation of GDC-9545 Monotherapy and Combination Therapy with Palbociclib and/or LHRH Agonist in Locally Advanced or Metastatic ER-Positive Breast Cancer
- Phase 3 Randomized Study of BGB‑43395 + Letrozole versus CDK4/6 Inhibitor Combination + Letrozole in Treatment‑Naïve Advanced HR+/HER2‑ Breast Cancer
Data & Insights
Has run more than one trial at 344 of 600 partner sites.
Specializations
Breast Cancer
Clinical research activity includes hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative breast cancer, with interest in both early-stage and advanced disease, as well as biomarker-defined subgroups such as PIK3CA mutation and ERBB2 alterations.
- Early and locally advanced breast cancer
- Metastatic HER2-positive and HER2-low disease
- Triple-negative and endocrine-resistant breast cancer
Work in this area also extends to recurrence risk stratification and treatment selection in node-positive breast cancer.
Thoracic and Lung Oncology
The investigator is involved in studies across non-small cell lung cancer, small cell lung cancer, and mutation-driven thoracic malignancies, including tumors with EGFR, ALK, ROS1, KRAS G12C, and RET alterations.
- Advanced and metastatic NSCLC
- Extensive-stage and limited-stage SCLC
- Genomically selected lung cancer
Research interest also includes metastatic squamous lung cancer and treatment options after prior targeted therapy or immunotherapy.
Hematologic Malignancies
Clinical trial involvement spans acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, multiple myeloma, and a broad range of B-cell lymphomas and Hodgkin lymphoma.
- Leukemia and myelodysplastic syndromes
- Multiple myeloma and plasma cell disorders
- Lymphoma, including mantle cell and diffuse large B-cell lymphoma
Additional activity includes cellular therapy and post-treatment follow-up in hematologic cancer care.
Gastrointestinal and Hepatobiliary Cancer
Her research landscape includes colorectal cancer, pancreatic ductal adenocarcinoma, gastric and gastroesophageal junction cancer, biliary tract cancer, and hepatocellular carcinoma, with attention to both localized and metastatic settings.
- Colorectal and pancreatic malignancies
- Gastric, esophageal, and biliary tract cancers
- Hepatocellular carcinoma and liver-related cancers
Interest also covers cholangiocarcinoma, advanced solid tumors of gastrointestinal origin, and biomarker-directed treatment strategies.
Autoimmune, Inflammatory, and Cardiometabolic Disease
Beyond oncology, the investigator is involved in trials for systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, and atopic dermatitis, alongside studies in multiple sclerosis and hidradenitis suppurativa.
- Autoimmune and inflammatory disorders
- Neurologic immune-mediated disease
- Cardiometabolic and liver-related conditions
Additional therapeutic interests include cardiovascular disease, obesity, chronic liver disease, and primary biliary cholangitis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.